clinical trial · NCT04965636
Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
GlaxoSmithKline·phase3·completed·n = 16
Hypereosinophilic SyndromeMepolizumab
brief summary
The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.
started
Jul 11, 2022
primary completion
Oct 28, 2025
completion
Oct 28, 2025
last updated
Dec 4, 2025
official title
A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol